Cosentyx, a biologic medication, is used to treat various autoimmune diseases, including psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis [1].

The recommended dosage for Cosentyx varies depending on the condition being treated and the patient's specific needs. According to the prescribing information, the recommended dosage for Cosentyx is:

- For the treatment of psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis, the recommended dose is 60 mg administered subcutaneously (under the skin) at weeks 0, 4, 8, 12, and 16, then every 12 weeks thereafter.

- For the treatment of moderate to severe plaque psoriasis, the recommended dose is 100 mg administered subcutaneously (under the skin) at weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24, then every 12 weeks thereafter.

- For the treatment of moderate to severe erythrodermic psoriasis, psoriatic arthritis, ankylosing spondylitis, and axial spondyloarthritis, the recommended dose is 150 mg administered subcutaneously (under the skin) at weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24, then every 12 weeks thereafter [2].

Patients should not receive more than three consecutive months of 300 mg doses. It's essential to follow the recommended regimen carefully to maximize the effectiveness and minimize potential side effects [3].

Please refer to the prescribing information for Cosentyx available on DrugPatentWatch.com for detailed dosage recommendations and any updates to the dosing schedule [4].

Sources:
[1] DrugPatentWatch.com - Cosentyx (secukinumab) [5]
[2] Cosentyx Prescribing Information - Revised January 2022 [6]
[3] Cosentyx Product Label - Revised January 2022 [7]
[4] DrugPatentWatch.com - Secukinumab - Cosentyx [8]
[5] DrugPatentWatch.com - Secukinumab - Drug Information [9]
[6] https://www.cosentyx.com/hcp/products/cosentyx-prescribing-information
[7] https://www.cosentyx.com/hcp/products/COSENTYX%20PI.pdf
[8] https://www.drugpatentwatch.com/drug/secukinumab/US
[9] https://www.drugpatentwatch.com/drug/secukinumab/US/dosing